NOVO'S SOGROYA® RECEIVES FDA APPROVAL AS THE FIRST AND ONLY ONCE-WEEKLY, LONG-ACTING GROWTH HORMONE FOR CHILDREN WITH TURNER SYNDROME (TS)

Reuters · 22h ago

Please log in to view news